16:51 EST Inhibikase Therapeutics (IKT) files to sell 58.31M shares of common stock for holders
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IKT:
- Inhibikase Therapeutics Reports Q3 2024 Financial Results
- Inhibikase Therapeutics reports Q3 EPS (65c), consensus (48c)
- Inhibikase Therapeutics, Inc. (IKT) Q3 Earnings Cheat Sheet
- Molson Coors upgraded, Rivian downgraded: Wall Street’s top analyst calls
- Inhibikase Therapeutics initiated with a Buy at Jefferies
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue